New Release: Autism - Pipeline Review, H1 2014
Upcoming SlideShare
Loading in...5

Like this? Share it with your network


New Release: Autism - Pipeline Review, H1 2014



Autism - Pipeline Review, H1 2014 @ ...

Autism - Pipeline Review, H1 2014 @

This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.



Total Views
Views on SlideShare
Embed Views



1 Embed 1 1


Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

New Release: Autism - Pipeline Review, H1 2014 Document Transcript

  • 1. Autism - Pipeline Review, H1 2014 Autism - Pipeline Review, H1 2014 Summary Global Markets Directs, Autism - Pipeline Review, H1 2014, provides an overview of the Autisms therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Autism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 8 list Of Figures 9 introduction 10 global Markets Direct Report Coverage 10 autism Overview 11 therapeutics Development 12 pipeline Products For Autism - Overview 12 pipeline Products For Autism - Comparative Analysis 13 autism - Therapeutics Under Development By Companies 14 autism - Therapeutics Under Investigation By Universities/institutes 17 autism - Pipeline Products Glance 19 late Stage Products 19 clinical Stage Products 20 early Stage Products 21 Autism - Pipeline Review, H1 2014
  • 2. unknown Stage Products 22 autism - Products Under Development By Companies 23 autism - Products Under Investigation By Universities/institutes 25 autism - Companies Involved In Therapeutics Development 26 f. Hoffmann-la Roche Ltd. 26 dainippon Sumitomo Pharma Co., Ltd. 27 novartis Ag 28 merz Pharma Gmbh & Co. Kgaa 29 teva Pharmaceutical Industries Limited 30 avanir Pharmaceuticals, Inc. 31 snowdon Inc. 32 curemark, Llc 33 coronado Biosciences, Inc. 34 omeros Corporation 35 intra-cellular Therapies, Inc. 36 cellceutix Corporation 37 heptares Therapeutics Ltd. 38 otsuka Holdings Co., Ltd. 39 reviva Pharmaceuticals Inc. 40 naurex, Inc. 41 nectid, Inc. 42 mnemosyne Pharmaceuticals, Inc. 43 biocrea Gmbh 44 saniona Ab 45 confluence Pharmaceuticals Llc 46 autism - Therapeutics Assessment 47 assessment By Monotherapy Products 47 assessment By Combination Products 48 assessment By Target 49 assessment By Mechanism Of Action 52 assessment By Route Of Administration 55 assessment By Molecule Type 57 drug Profiles 59 cm-at - Drug Profile 59 product Description 59 mechanism Of Action 59 r&d Progress 59 lurasidone Hydrochloride - Drug Profile 60 product Description 60 mechanism Of Action 60 r&d Progress 60 aripiprazole - Drug Profile 62 product Description 62 mechanism Of Action 62 r&d Progress 62 cycloserine - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 fluoxetine - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 oxytocin - Drug Profile 68 product Description 68 mechanism Of Action 68 r&d Progress 68 oxytocin - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 memantine Hydrochloride - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 tso - Drug Profile 73 product Description 73 mechanism Of Action 73 Autism - Pipeline Review, H1 2014
  • 3. r&d Progress 73 pioglitazone Hydrochloride - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 oxytocin - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 oxytocin - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 (dextromethorphan Hydrobromide + Quinidine Sulfate) - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 oxytocin - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 oxytocin - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 rg-7314 - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 fluoxetine - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 fluoxetine - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 argipressin Tannate - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 nu-211-01 + Nc-215-01 - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 autologous Hematopoietic Stem Cells - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 glatiramer Acetate - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 iti-007 - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 stem Cell Therapy For Central Nervous System Disorders - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 km-391 - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 program For Neurological Disorders - Drug Profile 100 product Description 100 mechanism Of Action 100 Autism - Pipeline Review, H1 2014
  • 4. r&d Progress 100 stx-110 - Drug Profile 101 product Description 101 mechanism Of Action 101 r&d Progress 101 cn-2097 - Drug Profile 102 product Description 102 mechanism Of Action 102 r&d Progress 102 acamprosate Calcium - Drug Profile 103 product Description 103 mechanism Of Action 103 r&d Progress 103 small Molecules To Inhibit Pi3k For Autism And Fragile X Syndrome - Drug Profile 104 product Description 104 mechanism Of Action 104 r&d Progress 104 small Molecule Targeting Mglur5 - Drug Profile 105 product Description 105 mechanism Of Action 105 r&d Progress 105 nr-2a Modulators - Drug Profile 106 product Description 106 mechanism Of Action 106 r&d Progress 106 autism Program - Drug Profile 107 product Description 107 mechanism Of Action 107 r&d Progress 107 small Molecule Targeting Gpr63 For Autism - Drug Profile 108 product Description 108 mechanism Of Action 108 r&d Progress 108 nrx-20xx - Drug Profile 109 product Description 109 mechanism Of Action 109 r&d Progress 109 drug Targeting Gaba Alpha 4 Delta Receptor For Autism And Sleep Disorders - Drug Profile 110 product Description 110 mechanism Of Action 110 r&d Progress 110 small Molecules To Positively Modulate Gabaa Receptor For Epilepsy And Autism - Drug Profile 111 product Description 111 mechanism Of Action 111 r&d Progress 111 drugs For Autism - Drug Profile 112 product Description 112 mechanism Of Action 112 r&d Progress 112 rp-5063 - Drug Profile 113 product Description 113 mechanism Of Action 113 r&d Progress 113 nrt-34 - Drug Profile 114 product Description 114 mechanism Of Action 114 r&d Progress 114 carbetocin - Drug Profile 115 product Description 115 mechanism Of Action 115 r&d Progress 115 oxytocin - Drug Profile 116 product Description 116 mechanism Of Action 116 r&d Progress 116 autism - Recent Pipeline Updates 117 autism - Dormant Projects 139 autism - Discontinued Products 140 Autism - Pipeline Review, H1 2014
  • 5. autism - Product Development Milestones 141 featured News & Press Releases 141 dec 12, 2013: Coronado Biosciences Announces Presentation Of Interim Data From Autism Study At Neuropsychopharmacology Meeting 141 nov 14, 2013: Stanford Drug Trial Seeks Participants With Autism Spectrum Disorder 141 nov 04, 2013: Curemark Begins Nda Submission For Cm-at Autism Treatment 142 sep 06, 2013: Avanir Pharmaceuticals Announces Settlement Of Nuedexta Patent Litigation With Wockhardt 142 sep 03, 2013: Avanir Pharmaceuticals Announces Settlement Of Nuedexta Patent Litigation With Actavis 143 aug 14, 2013: Avanir Pharmaceuticals Announces Settlement Of Nuedexta Patent Litigation With Sandoz 143 may 01, 2013: Seaside Therapeutics To Announce Results From Phase Iib Clinical Trial Of Arbaclofen In Autism Spectrum Disorder 144 apr 23, 2013: Curemark Announces Positive Pre-nda Meeting With Fda For New Drug Application For Cm-at For Autism 144 dec 03, 2012: Autism Speaks Awards $2m To Delsia For Partnership With Seaside Therapeutics To Develop Autism Treatments 145 nov 12, 2012: Coronado Biosciences Announces Initiation Of Investigator-initiated Study Evaluating Tso In Autism Spectrum Disorders 145 appendix 147 methodology 147 coverage 147 secondary Research 147 primary Research 147 expert Panel Validation 147 contact Us 148 disclaimer 148 ResearchMoz( is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: Website: Autism - Pipeline Review, H1 2014